Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q7L2E3

UPID:
DHX30_HUMAN

ALTERNATIVE NAMES:
DEAH box protein 30

ALTERNATIVE UPACC:
Q7L2E3; A8K5F1; O94965; Q7Z753; Q96CH4; Q9NUQ0

BACKGROUND:
The ATP-dependent RNA helicase DHX30 plays a significant role in nervous system development and differentiation. It is involved in the up-regulation of genes essential for neurogenesis, such as GSC, NCAM1, neurogenin, and NEUROD. Its function as an RNA-dependent helicase and its involvement in mitochondrial ribosomal subunit assembly underscore its critical role in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of ATP-dependent RNA helicase DHX30 could open doors to potential therapeutic strategies. Given its involvement in a neurodevelopmental disorder characterized by developmental delay and intellectual disability, research into DHX30 could pave the way for innovative treatments for such neurological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.